Managing IP is part of the Delinian Group, Delinian Limited, 8 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2023

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Australia: Omnibus claims and the doctrine of equivalents

For many years, Australia has allowed omnibus claims, which take the form of "an apparatus substantially as hereinbefore described…". They have been utilised as a last line of defence for patentees when suing defendants.

Unfortunately, Australia does not have a strong doctrine of equivalence, found for example, in US jurisprudence. Hence, we have tended towards a literal infringement of claims.

Any hope that the omnibus claim would assist in finding non-literal infringement of patent applications has recently been dashed by our Full Federal Court in GlaxoSmithKline Australia Pty Ltd v Reckitt Benckiser Healthcare (UK) Ltd [2016] FCAFC 90.

The subject matter of the case dealt with a spill-free syringe dispensing system, which dominated the consumer market. The defendants had invented around the main claim and had developed an alternate syringe that the trial judge found had "exactly the same function". Unfortunately, for the patentee, the defendant's modifications meant that there was no literal infringement of the main claims.

The trial judge held that the omnibus claim could be utilised in a doctrine of equivalence sense to cover the "substance" of the invention. The Full Court overruled the trial judge, and, as a result, severely curtailed the operation of omnibus claims. The Court noted the overriding requirement for the omnibus claim to not extend beyond what was covered by the claims.

As a consequence, omnibus claims (which have recently also been curtailed by our Patents Act), are significantly reduced in effectiveness. Also, our courts appear to be moving towards a literal infringement position of patent claims which will be of great concern to patentees.

treloar.jpg

Peter Treloar


Shelston IPLevel 21, 60 Margaret StreetSydney NSW 2000, AustraliaTel: +61 2 9777 1111Fax: +61 2 9241 4666email@shelstonip.comwww.shelstonip.com

more from across site and ros bottom lb

More from across our site

IP counsel urge the government to restrict safe harbour exceptions available to intermediaries and clear up doubts with the existing law
A New York lawyer could face sanctions after citing fake judgments generated by ChatGPT, but that doesn’t mean practitioners should shy away from AI
Klaus Grabinski told delegates at a UPC inauguration event that the proposed SEP regulation would limit access to justice
We provide a rundown of Managing IP’s news and analysis coverage from the week, and review what’s been happening elsewhere in IP
Sukanya Sarkar shares her thoughts on this year’s annual meeting in Singapore, where debates ranged from AI opportunities to improving law firm culture
The court’s ruling is a good reminder that US parties aren’t guaranteed attorney fees just because they win, say sources
With business confidence in a shaky state, Rachel Tan and Lisa Yong of Rouse discuss how in-house IP teams can manage their trademark portfolios through uncertain times
The Court of Appeal had stern words for Med-El’s representatives after they highlighted a deputy judge’s background as a solicitor
Funders and NPEs say asserting patent portfolios can minimise risk at the USPTO’s PTAB, where procedure remains a controversial topic
The US Supreme Court’s ruling wasn’t a surprise and reflects a trend that had already been bubbling away for a while, say tech and pharma counsel